Abstract:Dopamine is a neurotransmitter with an important role in forming long-lasting memories for some time, especially in episodic memory. Literature data show that dopamine receptor stimulation may be detrimental to spatial working memory functions in lab animals. (R)-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride derivative--SCH-23390 is a synthetic compound that acts as a selective, high-affinity antagonist of D1 receptors. Experimental studies suggest that SCH 23390 may prevent the spatial working memory disturbances induced by the active substances of marijuana. Melperone is an atypic antipsychotic drug presenting also dopaminergic D2 and 5-HT2A receptor antagonistic activity. This neuroleptic agent is used in the treatment of some types of schizophrenia. Aim: Experimental research on the effects of two dopamine receptor antagonists on spatial memory performance in rats. Material and methods: The experiment was carried out in white Wistar rats (200-250g), divided into 3 groups of 7 animals each, treated intraperitoneally with the same volume of solution for 14 days, as follows: Group I (Control): saline solution 0.1 ml/10g kbw; Group II (coded SCH): SCH-23390 0.3 mg/kbw; Group III (coded MLP): melperone 2 mg/kbw. The dopaminergic agent spatial memory performance was assessed by recording spontaneous alternation behavior in a single session in Y-maze. Each animal was placed at the end of one arm and allowed to move freely through the maze during an 8 min session. Alternation was defined as a consecutive entry in three different arms. The alternation percentage was computed with the following formula: number of alternations divided by total number of arm visits minus 2. Data were presented as +/- standard deviation and significance was tested by SPSS Statistics for Windows version 13.0 and ANOVA method. P-values less than 0.05 were considered statistically significant compared to those in the control group. Experimental researches were carried out in compliance with the regulations of our University Committee for Research and Ethical Issues. Results: SCH-23390 (0.3 mg/kbw) and melperone (2 mg/kbw) intraperitoneal injection for 14 days determined a statistically significant (p < 0.05 and p < 0.01, respectively) increase in spontaneous alternation rate (compared to controls in Y-maze test). Conclusions: Our research revealed that the 14 consecutive days administration of these two dopamine receptor antagonists was associated with the improvement of short-term memory in rats, more intense for SCH-23390 compound.

Synergistic Effect of Combined Treatment with Risperidone and Galantamine on Phencyclidine-Induced Impairment of Latent Visuospatial Learning and Memory: Role of Nachr Activation-Dependent Increase of Dopamine D1 Receptor-Mediated Neurotransmission

Synergistic Effect of Galantamine with Risperidone on Impairment of Social Interaction in Phencyclidine-Treated Mice As a Schizophrenic Animal Model.

The ameliorating effect of galantamine on cognitive impairment through nicotin-dopamine-ERK1/2 systems in mice treated with methamphetamine repeatedly

Galantamine Ameliorates The Impairment Of Recognition Memory In Mice Repeatedly Treated With Methamphetamine: Involvement Of Allosteric Potentiation Of Nicotinic Acetylcholine Receptors And Dopaminergic-Erk1/2 Systems

P4-240: Potentiation of calcium/calmodulin–dependent protein kinase I I benefits for cognitive enhancement in Alzheimer's disease patients

Cellular Mechanisms of Cognitive Enhancement: The In Vivo Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands

The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Ameliorates the Cognitive Dysfunction in Beta Amyloid25–35 I.c.v.-Injected Mice: Involvement of Dopaminergic Systems

The Effects of Donepezil on Phencyclidine-Induced Cognitive Deficits in a Mouse Model of Schizophrenia

The Allosteric Dopamine D1 Receptor Potentiator, DETQ, Ameliorates Subchronic Phencyclidine-Induced Object Recognition Memory Deficits and Enhances Cortical Acetylcholine Efflux in Male Humanized D1 Receptor Knock-in Mice.

Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242

PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats

Targeting α6GABAA receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal models

Effects of some dopamine antagonists on spatial memory performance in rats--experimental research

Finding the right dose: NMDAR modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity

Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson's disease dementia

Peripheral Cholinoceptor Antagonist Anisodamine Counteracts Cholinergic Adverse Effects and Facilitates Cognitive Amelioration of Rivastigmine

Synergistic Neuroprotective Effect of Schisandra chinensis and Ribes fasciculatum on Neuronal Cell Death and Scopolamine-Induced Cognitive Impairment in Rats

The Mglu5 Positive Allosteric Modulator LSN2463359 Differentially Modulates Motor, Instrumental and Cognitive Effects of NMDA Receptor Antagonists in the Rat

Attenuation of Scopolamine-Induced Deficits in Navigational Memory Performance in Rats by Bis(7)-Tacrine, a Novel Dimeric AChE Inhibitor.

Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action